ANTX on Nasdaq
AN2 Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $24.8M | $40.5M |
| General and administrative | $13.3M | $14.1M |
| Restructuring charges | $2.2M | |
| Total operating expenses | $38.1M | $56.8M |
| Loss from operations | -$38.1M | -$56.8M |
| Interest income | $2.9M | $5.5M |
| Other income | $1.0K | $1.0K |
| Net loss attributable to common stockholders | -$35.2M | -$51.3M |
| Net loss per share attributable to common stockholders, basic | -$1.16 | -$1.72 |
| Net loss per share attributable to common stockholders, diluted | -$1.16 | -$1.72 |
| Weighted-average number of shares used in computing net loss per share, basic | 30.2M shares | 29.8M shares |
| Weighted-average number of shares used in computing net loss per share, diluted | 30.2M shares | 29.8M shares |
| Unrealized gain (loss) on investments | $26.0K | -$244.0K |
| Comprehensive loss | -$35.1M | -$51.6M |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $19.9M | $21.4M | |
| Short-term investments | $38.1M | $62.3M | |
| Prepaid expenses and other current assets | $1.9M | $2.6M | |
| Total current assets | $59.9M | $86.3M | |
| Long-term investments | $2.0M | $5.0M | |
| Other assets, long-term | $0 | $804.0K | |
| Total assets | $62.0M | $92.1M | |
| Accounts payable | $3.0M | $3.3M | |
| Accrued compensation | $2.4M | $1.7M | |
| Accrued liabilities | $2.1M | $4.5M | |
| Other current liabilities | $1.2M | $791.0K | |
| Total current liabilities | $8.7M | $10.2M | |
| Other non-current liabilities | $170.0K | $0 | |
| Total liabilities | $8.9M | $10.2M | |
| Additional paid-in capital | $294.0M | $287.6M | |
| Accumulated other comprehensive gain | $57.0K | $31.0K | |
| Accumulated deficit | -$240.9M | -$205.8M | |
| Total stockholders' equity | $53.1M | $81.8M | $124.7M |
| Total liabilities and stockholders' equity | $62.0M | $92.1M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 27.4M shares | 29.9M shares | |
| Common stock, shares outstanding | 27.4M shares | 29.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$35.2M | -$51.3M |
| Stock-based compensation expense | $6.2M | $8.3M |
| Net accretion of discount on investments | -$1.1M | -$3.3M |
| Prepaid expenses and other assets | $1.5M | $807.0K |
| Accounts payable | -$296.0K | $641.0K |
| Accrued compensation | $742.0K | -$2.3M |
| Accrued liabilities | -$2.4M | -$2.2M |
| Other current liabilities | $438.0K | $126.0K |
| Other non-current liabilities | $170.0K | |
| Net cash used in operating activities | -$29.8M | -$49.3M |
| Purchases of investments | -$46.2M | -$46.8M |
| Maturities of investments | $74.5M | $101.3M |
| Net cash provided by investing activities | $28.3M | $54.6M |
| Proceeds from issuance of common stock under the ESPP | $86.0K | $147.0K |
| Proceeds from exercise of stock options | $27.0K | $225.0K |
| Net cash provided by financing activities | $113.0K | $372.0K |
| Net (decrease) increase in cash and cash equivalents | -$1.4M | $5.7M |
Recent filings
- Oct 13, 20264
- Oct 13, 20264
- Oct 13, 20264
- Sep 16, 20264
- Sep 14, 2026S-8
- Sep 11, 20264
- Sep 8, 20264
- Sep 4, 20264
- Sep 2, 20264
- Aug 27, 20263
- Aug 19, 20264
- Aug 17, 2026144
- Aug 14, 20264
- Aug 11, 20268-K
- Aug 11, 202610-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8